News

Jost B. Jonas, MD, has been named the 2011 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma.

STAAR Surgical Co. has received CE mark approval for a single-piece toric IOL (nanoFLEX Toric Collamer Single Piece IOL). The IOL, which is designed for patients who have cataracts and astigmatism, was approved for correction of 1.0 D to 4.0 D of cylinder in 0.5-D steps.

Iridex Corp. has entered into a license and distribution agreement with Alcon. The agreement covers a line of cannula products used in vitrectomy procedures (GreenTip Soft Tip Cannula) and license rights to the associated patented technology.

Patient enrollment has begun in a phase III clinical trial of ISV-502 (AzaSite Plus, InSite Vision) and ISV-305 (DexaSite, InSite Vision) to evaluate the efficacy and safety of both product candidates simultaneously for the treatment of blepharitis. The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study will seek to enroll approximately 900 patients with moderate-to-severe blepharitis in a four-arm trial.

The FDA has cleared a spectral-domain optical coherence tomography (OCT) device (RTVue, Optovue) to measure central corneal power, curvature, and thickness in human corneas, before and after cataract surgery.

The FDA has granted orphan drug designation to sirolimus (DE-109, Santen) for the treatment of chronic/refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis, and non-infectious uveitis affecting the posterior segment of the eye.

The FDA has approved the recombinant fusion protein aflibercept (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of patients with neovascular age-related macular degeneration (AMD).

A hydrogel liquid ocular bandage, designed to seal corneal incisions after cataract surgery, provided a smooth, soft, and transparent protective barrier film that may improve wound integrity and closure and did not decrease best-corrected visual acuity.

Laser may treat presbyopia

Accommodation restoration through photodisruption of the crystalline lens using an ultra-short-pulse femtosecond laser appears safe and theoretically possible.

Analyses of data from a German CE study show femtosecond laser-based intrastromal correction of presbyopia results in significant improvement in near vision and high patient satisfaction with stable refractive outcomes for at least 2 years.

Enhanced laser vision correction surgery using a platform combining wavefront-guided ablation, iris registration, and femtosecond laser flap creation delivers excellent refractive and vision outcomes resulting in highly satisfied patients.

Advanced technology from Schwind is already shaping the future of refractive surgery, but surgeons can look forward to further refinements and innovations that will offer additional capabilities.

Lower prices = more sales?

Running sales can be financially counterproductive if they do not bring in new customers and only reduce the price that existing customers pay for products they buy.

Monofocal IOLs provide good distance and near visual acuities of about 20/40 or better for pediatric patients when the targeted vision is within 1 D of emmetropia.

Tubing enhances phaco

Enhanced low-compliance tubing on a proprietary phaco platform may help to increase vacuum limit safely and allow the surgeon to lower the bottle height or decrease the incision size with greater stability and safety without reduced ergonomic convenience.

Anti-VEGF agent aids DME

A 1-year extension of a two-year phase II study of treatment of diabetic macular edema allowed ranibizumab dosing frequency to increase from every 2 or 3 months to monthly.

Laser upgrade launched

Topcon Medical Laser Systems Inc. has launched a system upgrade for its family of lasers offering scanning technology and tissue-sparing sub-threshold treatment options.

NSAID aids anti-VEGF drug

Results of a prospective, randomized pilot study suggest that a topical nonsteroidal anti-inflammatory drug, bromfenac 0.09%, may be a useful addition to an anti-vascular endothelial growth factor agent, intravitreal ranibizumab, in patients being treated for exudative age-related macular degeneration.

The UV + riboflavin crosslinking procedure triggers the development of mild stromal haze in rabbit corneas, but it is not because of myofibroblast generation,a s it is for late haze after PRK.